Merck Cash on Hand 2010-2023 | MRK

Merck cash on hand from 2010 to 2023. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
  • Merck cash on hand for the quarter ending December 31, 2023 was $7.093B, a 46.23% decline year-over-year.
  • Merck cash on hand for 2023 was $7.093B, a 46.23% decline from 2022.
  • Merck cash on hand for 2022 was $13.192B, a 62.94% increase from 2021.
  • Merck cash on hand for 2021 was $8.096B, a 0.57% increase from 2020.
Merck Annual Cash on Hand
(Millions of US $)
2023 $7,093
2022 $13,192
2021 $8,096
2020 $8,050
2019 $10,450
2018 $8,864
2017 $8,498
2016 $14,341
2015 $13,427
2014 $15,719
2013 $17,486
2012 $16,141
2011 $14,972
2010 $12,201
2009 $9,604
Merck Quarterly Cash on Hand
(Millions of US $)
2023-12-31 $7,093
2023-09-30 $8,773
2023-06-30 $6,378
2023-03-31 $10,387
2022-12-31 $13,192
2022-09-30 $11,248
2022-06-30 $10,128
2022-03-31 $8,928
2021-12-31 $8,096
2021-09-30 $10,016
2021-06-30 $8,575
2021-03-31 $6,981
2020-12-31 $8,050
2020-09-30 $7,356
2020-06-30 $11,103
2020-03-31 $7,432
2019-12-31 $10,450
2019-09-30 $8,018
2019-06-30 $7,105
2019-03-31 $8,798
2018-12-31 $8,864
2018-09-30 $10,285
2018-06-30 $7,594
2018-03-31 $7,346
2017-12-31 $8,498
2017-09-30 $11,195
2017-06-30 $11,967
2017-03-31 $15,249
2016-12-31 $14,341
2016-09-30 $13,067
2016-06-30 $11,834
2016-03-31 $12,943
2015-12-31 $13,427
2015-09-30 $12,089
2015-06-30 $11,370
2015-03-31 $15,601
2014-12-31 $15,719
2014-09-30 $14,347
2014-06-30 $13,395
2014-03-31 $20,513
2013-12-31 $17,486
2013-09-30 $18,169
2013-06-30 $18,098
2013-03-31 $16,022
2012-12-31 $16,141
2012-09-30 $18,117
2012-06-30 $17,450
2012-03-31 $15,566
2011-12-31 $14,972
2011-09-30 $15,576
2011-06-30 $13,981
2011-03-31 $13,029
2010-12-31 $12,201
2010-09-30 $10,625
2010-06-30 $9,943
2010-03-31 $9,777
2009-12-31 $9,604
2009-09-30 $22,256
2009-06-30 $16,932
2009-03-31 $12,582
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $318.503B $60.115B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $714.182B 118.93
Novo Nordisk (NVO) Denmark $558.743B 46.03
Johnson & Johnson (JNJ) United States $355.491B 14.14
AbbVie (ABBV) United States $287.341B 14.61
AstraZeneca (AZN) United Kingdom $213.711B 18.94
Novartis AG (NVS) Switzerland $198.225B 13.73
Pfizer (PFE) United States $146.433B 14.13
Sanofi (SNY) $116.185B 10.46
Innoviva (INVA) United States $0.925B 6.53